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Abstract
The infiltration of immuno-inflammatory cells is one of the earliest and durable steps that lead to
atherosclerosis. These cells produce many immune components that act as a double-edged sword in
this inflammatory disease. Among these components, we note antimicrobial peptides, including defenses.
Defenses are natural cationic peptides of the innate immune system. In Humans, these small peptides
have a large antimicrobial spectrum. In addition, they play an important role in both infectious and
inflammatory diseases. Our objective was to study the relation between alpha-defenses (DEFA) 1-3 genes
expression and cardiovascular risk factors. This objective was built on the hypothesis that defenses may
be involved in cardiovascular pathologies, and may serve as a new generation of biomarkers. To verify this
hypothesis, we treated HL-60 differentiated cells with glucose decreased alphadefenses 1, 2 and 3 gene
expression levels, while insulin treatment restored its expression. These findings suggest that DEFA1-3
are involved in the complex glucose-insulin metabolic pathway. In summary, DEFA1-3 genes expression
is significantly correlated with glucose. These findings we suggest that DEFA1-3 could be involved in the
evolution of cardiovascular complications.
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ABSTRACT: The infiltration of immuno-inflammatory cells is one of the earliest and durable
steps that lead to atherosclerosis. These cells produce many immune components that act as
a double-edged sword in this inflammatory disease. Among these components, we note
antimicrobial peptides, including defenses. Defenses are natural cationic peptides of the
innate immune system. In Humans, these small peptides have a large antimicrobial spectrum.
In addition, they play an important role in both infectious and inflammatory diseases. Our
objective was to study the relation between alpha-defenses (DEFA) 1-3 genes expression and
cardiovascular risk factors. This objective was built on the hypothesis that defenses may be
involved in cardiovascular pathologies, and may serve as a new generation of biomarkers.
To verify this hypothesis, we treated HL-60 differentiated cells with glucose decreased alphadefenses 1, 2 and 3 gene expression levels, while insulin treatment restored its expression.
These findings suggest that DEFA1-3 are involved in the complex glucose-insulin metabolic
pathway. In summary, DEFA1-3 genes expression is significantly correlated with glucose.
These findings we suggest that DEFA1-3 could be involved in the evolution of cardiovascular
complications.
KEYWORDS: Antimicrobial peptides, alpha-defences 1, 2 and 3, inflammation, atherosclerosis,
cardiovascular diseases.
1. INTRODUCTION
Antimicrobial peptides (AMPs) are considered key components of the innate immune defense system in
multicellular organisms (1). They have a broad spectrum of antibacterial and antifungal activity,
even antiviral. Currently, in multicellular organisms, there are more than 1000 AMPs (M. Zaiou, 2007).
Among many classes of AMPs in humans, two classes are well characterized: defences and cathelicidin (M.
Zaiou, 2007). The cathelicidin is a major class of AMPs in mammals. They are synthesized as human precursor
cathelicidin antimicrobial protein -18 KDa (hCAP-8) (M. Zaiou, 2007). Defensins are produced in abundance
by the tissues involved in body defense, such as the skin, the intestinal mucosa, and the mucous membranes of
the respiratory (M. Zaiou, 2007). In humans, these peptides are divided into two groups: alpha and β-defensins
(M. Zaiou, 2007).
The – defences (DEFA) are abundant in atherosclerotic plaques: a study has shown that elevated levels
of DEFA deposited in the skin are associated with a high risk of cardiovascular morbidity and mortality in
diabetic patients (G. Joseph, 2008). This suggests that DEFA may act as risk markers for cardiovascular
diseases (CVDs) (G. Joseph, 2008). Similarly, the expression of LL-37 has been shown to be a key
peptide favoured cardiovascular risk (Ciornei, 2006). Its abundance at the level of atheromatous plaques and
its apoptotic activity on smooth muscle cells could lead to the weakening of the cell cluster, and facilitating the
formation of thrombi under the action of blood pressure (Ciornei, 2006). A study published by Benachour et
al., showed that the expression of LL-37 was associated with cardiovascular risks, such as the Body Mass Index
(BMI), waist circumference, Glucose level, Blood pressure, High-Density rates Lipoprotein-Cholesterol
(Benachour et al., 2009). All these results suggest that the expression of AMPs could be associated with the
syndrome metabolic, which is complicated by CVDs (Benachour et al., 2009).
Since the immune system and inflammation are part of the processes that contribute to the development
of CVDs, and defensins seem to be involved in the regulation of lipid metabolism, a better understanding of
the functions of these peptides in this context would be possible. Thus, we intended to the association between
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the expression of the genes of DEFA1-3 and the cardiovascular risk factors; mainly glucose through
establishing a cellular model for the study of the regulation of DEFA1-3 expression.
2. METHODS
2.1 Cell Models
2.1.1 The culture of U-937 and HL-60 lines
The cells are stored at -196°C. in liquid nitrogen, in RPMI 1640 medium supplemented with 10%
of the Fetal Bovine Serum (FBS) (lineage U-937) and 15% FCS (lineage HL-60) with 10% DMSO. After
rapid thawing in a water bath at 37oC, the cell suspension is introduced into a 15ml flask containing RPMI
1640 medium prepared beforehand, then centrifuged for 5 min at 200g to remove traces of DMSO. The
cell pellet obtained is re-suspended in the medium complete RPMI 1640 then put back in culture in flasks
of 25cm2 with a final volume 8ml of the corresponding medium. The U-937 cell line is cultivated in
medium RPMI 1640 supplemented with 10%, in contrast, the HL-60 cell line is cultured in RPMI 1640
medium supplemented with 15%. Once confluent, cultured cells are sub-cultured approximately every 2
days (d) then incubated at 37oC with 5% CO2.
2.1.2 Semi-quantitative RT-PCR analysis
a- Reverse transcription of mRNAs
200ng of total RNA is mixed with the enzyme buffer and 500ng/μl of oligodT are added.
b- PCR amplification semi-quantitative
To quantify the expression of DEFA1-3, the PCR is carried out in a reaction mixture
containing: 0.25μM sense and antisense primer, buffer 1x MgCl2, dNTPs 0.2μM, and Taq polymerase
2U/μl. The PCR was carried out in a thermocycler I- cycler and lasts 30 cycles. PCR conditions
include DNA denaturation step at 95oC for 30 sec, hybridization at 63oC, and an elongation stage at
72oC for 30 sec. This protocol was used to quantify Cluster of Differentiation genes (CD14), 11b and
the 18S gene.
2.3 Statistical analyzes
Statistical analyzes were performed with the SAS software (SAS Institute Inc). The verification of
the normality of the distribution of values of the studied parameters was realized by the calculation of the
dissymmetry coefficients (Skewness). To analyze the difference between DEFA1-3 in HL-60 cells when
treated with glucose we used student t test. For all analyzes, the threshold significance was set at P<0.05.
3. RESULTS
In order to identify the cell line expressing DEFA1-3, total RNA was extracted from HL-60 and U-937
cells. Semi-quantitative RT-PCR analysis showed that DEFA1-3 are expressed only in the HL-60 cell line and
not in line U-937. Since macrophages and neutrophils contribute to the development of the inflammatory
process of atherosclerosis, we have differentiated HL-60 cells into macrophages and neutrophils. We chose to
treat HL-60 cells with 1, 2 and 13% DMSO to induce differentiation of pro-myeloblasts HL-60 in neutrophils
(Figure 1).
A- Schematization of HL-60 cells differentiation to neutrophils when treated with DMSO. BMorphological changes detected by May-Grunwald Giemsa staining after 4 days of treatment with 1.2%
DMSO. Cells differentiated into neutrophils are smaller in size and have a segmented nucleus. C-RT-PCR
analysis of the expression of the CD11b gene in HL-60 cells treated with 1.2% DMSO for 4 and 5 days, shows
induction as early as 4 days to reach a maximum at 5 days after treatment. D- The RT-PCR analysis of the
expression of the CD11b gene in the HL-60 cells treated with 1.3% of DMSO, shows a maximum of induction
of the expression of the CD11b gene from 3 to 4 days later.
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Fig 1. Analysis of the differentiation of HL-60 cells into neutrophils after treatment with
dimethylsulfoxide.
To initiate the differentiation of HL-60 pro-myeloblasts into macrophages, we treated these cells with
PMA, a compound known for its ability to differentiate U-937, and HL-60 into macrophages. The analysis of
DEFA1-3 expression by semi-quantitative RT-PCR showed that undifferentiated HL-60
cells consistently expressed this gene. On the other hand, we found a complete inhibition of DEFA during
the differentiation of HL-60 into macrophages (not shown). As for the differentiation of HL-60 in neutrophils,
it did not affect the expression of DEFA1-3. Expression levels similar to those found in pro-myeloblasts have
been detected (Figure 2).
DEFA1-3 gene expression
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Fig 2. Analysis of the expression of alpha-defensin genes 1-3 in HL-60 cells differentiated into
neutrophils and macrophages.
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The HL-60 cells were differentiated into neutrophils and macrophages following treatment with 1.2%
DMSO for 5 days and with 100 nM PMA for 24 hours respectively.
HL-60 differentiated
into
neutrophil cells were
treated
with
concentrations
of
4.5mM and 10mM glucose. The duration of treatment with these different concentrations of glucose was 6
h. This duration of treatment mimics the post-meal stage of the human organism, following the administration
of the meal. It is characterized by a minimal secretion of insulin and therefore by the presence of high levels
of glucose in the body. Treatment of HL-60 differentiated into neutrophils with 10 mM glucose during 6 hours
decreased the levels of DEFA1-3 expression by comparison to control (P<0.001) (Figure 3).
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Fig3. Effect of glucose and insulin treatment on alpha-defensin 1-3 gene expression in HL-60 cells
differentiated into neutrophils.
HL-60 cells differentiated into neutrophils were treated with increasing concentrations of glucose (4.5mM and
10mM), in the absence or in the presence of 150nM insulin. Cells previously incubated with the three increasing
glucose concentrations were treated with 150nM insulin for 6 h. DEFA1-3 gene values were normalized to the
18S gene. Bilateral correlation coefficients were calculated with P* <0.05 and P** <0.001.
After treatment of the cells with the same concentrations of glucose and insulin at a concentration of
150nM, semi-quantitative PCR analysis was showed that insulin has an opposite effect to that of glucose on
the expression of DEFA1-3. Indeed, a doubling of the level of mRNA of DEFA1-3 was observed in insulintreated cells compared to cells grown under hyperglycemic conditions only (Figure 3). We thus demonstrate
an in vitro regulation of DEFA1-3 in HL-60 cells differentiated into neutrophils by glucose and insulin.

4. DISCUSSION
Our observations are consistent with other studies showing that defensins are overexpressed
in human atherosclerotic lesions and that their level of expression is correlated with the degree of severity
of CVDs (Lopez-Bermejo, 2007). Unlike the associations we have described, a recent study shows that obesity
and smoking decrease the concentration of DEFA1-3 in plasma and high concentrations of these peptides are
associated with a reduction in LDL cholesterol and total cholesterol (P. Libby, 2002). The differences between
the two studies could be explained by the fact that these authors assayed defensins at the protein level in the
plasma, while in our case, we measured the mRNA expression of defensins in specific cells, PBMCs. For
these reasons, additional studies either on larger populations as well as subjects suffering from well-defined
pathologies (hypertension, diabetes, obesity) on an animal or cellular model, will be necessary to allow access
to mechanisms for the release and action of AMPs and to understand their role that could be atherogenic or
pro-atherogenic. In this perspective and to understand the relationship between defensins and studied clinical
parameters, we initiated the study of the regulation of these peptides in the HL-60 cell line in response to
different stimuli including glucose. The HL-60 cells are pro-myeloblasts that express DEFA1-3. They
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are immature cells that normally mature in the bone marrow before gaining blood circulation, their
differentiation into neutrophils and macrophages is necessary (P. Libby, 2002).
Differentiation of HL-60 cells into neutrophils did not affect the expression of DEFA1-3 since similar
levels of expression those observed at the pro-myeloblast stage were detected. For these reasons, we
have chosen the HL-60 neutrophil model as the leukocyte type valid for study the possible regulation
of DEFA1-3 during the inflammatory process linked to atherosclerosis.
In order to understand the relationship between glucose and DEFA1-3 expression levels, we differentiated
HL-60 cells into neutrophils. We found that glucose significantly decreases the expression of DEFA1-3
mRNA. This decrease was restored when insulin was added in the culture medium. These observations suggest
a role for DEFA1-3 in the metabolic pathways of glucose and insulin. Our preliminary results are consistent
with a recently published study (Froy, 2007). Using a mouse model of diabetes, Froy et al., observed low levels
of β - defensin 1 at the renal level and that were re-standardized by treatment with insulin (Froy, 2007).
5. CONCLUSIONS
To conclude, our results demonstrated that glucose might change DEFA1-3 gene expression in HL-60
cells. .
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